Seminars in Arthritis and Rheumatism
Volume 40, Issue 3 , Pages 193-200, December 2010

Osteoporosis and Cardiovascular Disease Care in Systemic Lupus Erythematosus According to New Quality Indicators

  • Kristina L. Demas, BA

      Affiliations

    • George Washington School of Medicine, Washington, DC
  • ,
  • Brendan T. Keenan, MPH

      Affiliations

    • Brigham and Women's Hospital, Division of Rheumatology, Immunology and Allergy, Boston, MA
  • ,
  • Daniel H. Solomon, MD, MPH

      Affiliations

    • Brigham and Women's Hospital, Division of Rheumatology, Immunology and Allergy, Boston, MA
  • ,
  • Jinoos Yazdany, MD, MPH

      Affiliations

    • UCSF, Division of Rheumatology, San Francisco, CA
  • ,
  • Karen H. Costenbader, MD, MPH

      Affiliations

    • Brigham and Women's Hospital, Division of Rheumatology, Immunology and Allergy, Boston, MA
    • Corresponding Author InformationAddress reprint reprints to: Karen H. Costenbader, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115

published online 09 April 2010.

Objectives

Quality indicators (QIs) for the assessment of care of patients with systemic lupus erythematosus (SLE) have been proposed. We evaluated care according to these proposed QIs for osteoporosis and cardiovascular disease (CVD) in patients with SLE in our rheumatology practice.

Methods

We selected 200 patients with SLE according to American College of Rheumatology Criteria and ≥2 visits to our practice in 2007 to 2008. We performed a structured medical record review and collected demographics, SLE and past medical history, medications, laboratories and data concerning osteoporosis, and CVD management. We employed univariable analyses and multivariable regression analyses to test for factors associated with care meeting the proposed QIs.

Results

Ninety-four percent of patients were female and 64% were white. Mean age was 46.3 years and mean lupus duration was 15.3 years. Twenty-nine percent were taking ≥7.5 mg prednisone per day for ≥3 months. The proportions of patients for whom care met the proposed QIs were as follows: 59% for bone mineral density testing, 62% for calcium and vitamin D supplementation, and 86% for antiresorptive or anabolic osteoporosis medications. Only 3% had 5 cardiac risk factors assessed within the year and 26% had 4 cardiac risk factors assessed annually. Smoking, fasting lipid panels, and diabetes mellitus were rarely assessed annually. Having a primary care physician within our health care network increased care meeting QIs.

Conclusions

Care according to newly proposed QIs for osteoporosis and CVD was suboptimal in our academic center. To standardize and improve care of patients with SLE, we suggest specific changes to the proposed QIs.

Keywords: systemic lupus erythematosus, quality indicator, osteoporosis, cardiovascular disease, bone mineral density, screening, cholesterol, blood pressure, management, risk factor, calcium and vitamin D

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by NIH Grants P60 AR047782, K24 AR055989-01, BIRCWH K12 HD051959 (supported by NIMH, NIAID, NICHD, and OD). Ms. Demas was the recipient of a Lupus Foundation or New England/Arthritis Foundation of Massachusetts jointly sponsored summer student award.

PII: S0049-0172(10)00005-3

doi:10.1016/j.semarthrit.2010.01.001

Seminars in Arthritis and Rheumatism
Volume 40, Issue 3 , Pages 193-200, December 2010